Clinical pharmacy is a patient-centered discipline and improves significantly the safety of drug management. Regarding medications, clinical pharmacy is efficient. The investigator hypothesize that clinical pharmacy applied to medical devices could be as effective as in the medication field. The main objective of this study is to assess the effectiveness of clinical pharmacy activities during entire care pathways of patients implanted with a PICC line, in preventing complications.
This is a preliminary, before-after, monocentric and prospective study. The study will begin with an observational period and will be followed by an experimental intervention period. Sixty-nine adult patients in each period will be included. During the observational phase, no clinical pharmacy activities will be performed. During the interventional phase, clinical pharmacists will be active during the entire patients' care pathways.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
138
PICC line implantation: Optimize the logistics circuit of the PICC line by rationalizing orders through the evaluation of potential losses. Ensure the due traceability of the implanted medical device. Discharge order : Analysis, optimization and pharmaceutical interventions if necessary Discharge Pharmaceutical Interview : Discussion with the patient, Information about the PICC line maintenance and associated therapies, Information about the prescribed drugs. Call to the community pharmacist to transfer the patient's prescription. Follow-up calls for 3 months after discharge * Patients: Two calls the first week after implantation, then one call per month for a maximum of 3 months, Clinical data collection :Pharmaceutical advices if necessary * Liberal nurses: same frequency, Clinical data collection, Pharmaceutical advices if necessary * Community pharmacist: one call per month, information relevant to the patient's follow-up will be collected.
CIVADE
Toulouse, Occitanie, France
Assessment of the number of complications during the interventional phase.
Number of complications per patient and per month in each group. Number of complications per patient and per month in each group
Time frame: 3 months
Number of consultations and rehospitalizations post-discharge.
Rates of consultations and rehospitalizations in each group.
Time frame: 3 months
Acceptance rate of pharmaceutical interventions (PI) during interventional phase and evaluation of PIs' criticality.
Number of potentially inappropriate prescriptions resulting in an accepted PI over total of PIs.
Time frame: 3 months
Conformity analysis of the PICC line logistic circuit
Number of correct items over total (items checklist about stock, supply chain, traceability)
Time frame: day 0
Conformity analysis of treatment indication.
Number of correct items over total (items checklist about recommended indications, implantation duration, etc.)
Time frame: day 0
Conformity analysis of hospital prescriptions issued in town.
Conformity rates per phase.
Time frame: day 0
Patient's Quality Of Life assessment
EQ-5D-5L score
Time frame: at discharge
Patient's Quality Of Life assessment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
EQ-5D-5L score
Time frame: 3 months
Participants satisfaction survey
Assessment of patients' satisfactions regarding their therapeutic management
Time frame: 3 months
healthcare professionals satisfaction survey
assessment of healthcare professionals' satisfactions regarding their collaboration with the pharmacists
Time frame: 3 months
Direct hospital costs.
description and evaluation of the direct medical costs
Time frame: 3 months